Trina Solar Limited (NYSE:TSL): A mid-year subsidy change has been approved by the German government for photovoltaic solar installations in rooftops, and it will continue driving solar demand for the rest of 2012. However, there is no year-end rally expected that will boost overall PV capacity for the country, research firm iSuppli predicted earlier today. New legislation will probably prevent a year-end scramble from occurring, and only 28 percent of installations slated for 2012 will take place during Q4, the firm added. The shares closed at $4.28, down $0.31 or 6.75% on the day. They have traded in a 52-week range of $4.34 to $16.78.
Don’t Miss: Revelations on the New iPhone.
Ultralife Corp. (NASDAQ:ULBI): For 2012, management keeps expecting high-single to low-double digit year-over-year revenue growth in its Communication Systems segment and China operations, but, because of the ongoing softness in the Battery & Energy Products segment, the company’s largest segment, management predicts year-over-year total sales will fall by 20 percent to 30 percent. Having taken actions to lower spending and align capacity, management thinks that a return to operating profitability for the 2H of 2012 is achievable with an operating margin in the low- to mid-single digits. The magnitude of the 1H operating loss is predicted to result in a total year operating loss. Management cautions that the timing of orders and shipments could also cause variability in quarterly results. The shares closed at $3.19, down $0.7 or 17.99% on the day. They have traded in a 52-week range of $3.41 to $5.50.
Visteon Corp. (NYSE:VC) completed the sale of its automotive lighting business to Varroc Group, who is a global provider of automotive parts, for $72 million in cash, subject to price adjustments. The two companies announced intentions for the sale on March 12. The shares closed at $28.61, down $4.08 or 12.48% on the day. They have traded in a 52-week range of $28.71 to $62.38.
Veolia Environnement (NYSE:VE) decided to increase its efforts for cost-reduction and lowered its investments by EUR500 million from 2012 to 2013, according to the Wall Street Journal. The shares closed at $9.95, down $1.27 or 11.32% on the day. They have traded in a 52-week range of $10.09 to $17.65.
Vanda Pharmaceutical (NASDAQ:VNDA) reports a Q2 EPS of 28c, one estimate (27c). The shares closed at $4.06, up $0.1 or 2.53% on the day. They have traded in a 52-week range of $3.93 to $7.07.
Don’t Miss: Apple’s iPad is A Growth ANIMAL.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
Learn More
There's always a bull market in some sector! Find the best opportunities in commodities.
Learn more
At last, a trading system that buys the right ETFs at the right time, time after time!
Learn more